Wyeth and Santaris have entered into an agreement to develop new drugs based on Santaris’ Locked Nucleic Acid drug platform that could treat protein-related diseases. Wyeth is diversifying into biotech and this deal adds another technology to increase the company’s capability to bring new drugs onto the market.